GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Gross Profit

Chordate Medical Holding AB (OSTO:CMH) Gross Profit : kr1.31 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Gross Profit?

Chordate Medical Holding AB's gross profit for the three months ended in Dec. 2023 was kr0.31 Mil. Chordate Medical Holding AB's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was kr1.31 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Chordate Medical Holding AB's gross profit for the three months ended in Dec. 2023 was kr0.31 Mil. Chordate Medical Holding AB's Revenue for the three months ended in Dec. 2023 was kr0.48 Mil. Therefore, Chordate Medical Holding AB's Gross Margin % for the quarter that ended in Dec. 2023 was 63.69%.

Chordate Medical Holding AB had a gross margin of 63.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 9 years, the highest Gross Margin % of Chordate Medical Holding AB was 406.80%. The lowest was -4.87%. And the median was 134.12%.


Chordate Medical Holding AB Gross Profit Historical Data

The historical data trend for Chordate Medical Holding AB's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB Gross Profit Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only 2.07 2.51 1.93 0.03 1.31

Chordate Medical Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.09 0.40 0.51 0.31

Competitive Comparison of Chordate Medical Holding AB's Gross Profit

For the Medical Devices subindustry, Chordate Medical Holding AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's Gross Profit distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's Gross Profit falls into.



Chordate Medical Holding AB Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Chordate Medical Holding AB's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.976 - -0.333
=1.31

Chordate Medical Holding AB's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.482 - 0.175
=0.31

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.31 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Chordate Medical Holding AB's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.31 / 0.482
=63.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Chordate Medical Holding AB  (OSTO:CMH) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Chordate Medical Holding AB had a gross margin of 63.69% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Chordate Medical Holding AB Gross Profit Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines